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ABSTRACT
EglN2 contributes to ERα-positive breast tumorigenesis by acting as an estrogen-
inducible gene. However, the detailed molecular mechanism(s) underlying the 
post-transcriptional regulation of EglN2 and its potential role in Triple Negative 
Breast Cancer (TNBC) remains largely unclear. By using C3Tag transgenic mice and 
tumor-derived C3Tag cell line, here we report that EglN2 contributes to TNBC tumor 
progression and genetic knockout of EglN2 improves C3Tag mice survival from tumor 
progression. Mechanistically, we further show that FBW7, an E3 ligase complex 
component that is frequently downregulated in TNBC, negatively regulates EglN2 
protein stability. As such, depletion of FBW7 in breast cell lines leads to upregulation 
of EglN2 and other canonical FBW7 substrates. Conversely, FBW7 overexpression 
leads to EglN2 downregulation in a GSK3β-dependent manner. Furthermore, we 
identified some potential serine or threonine residues on the C-terminal of EglN2 that 
may mediate its binding and potential regulation by FBW7. Together, our study reveals 
that EglN2 might act as an FBW7 ubiquitin ligase substrate contributing to TNBC.
INTRODUCTION
Triple Negative Breast Cancer (TNBC), the subtype 
tested negative for estrogen receptors (ER), progesterone 
receptors (PR) or Her2, accounts for 15-25% of breast 
cancers [1, 2]. It is more likely to affect younger people, 
African Americans and those with a BRCA1 gene 
mutation [1, 2]. TNBC is well known for its aggressive 
clinical behavior and early peak of disease recurrence. 
Furthermore, TNBC does not respond to endocrine 
therapy, such as Tamoxifen or aromatase inhibitors, or 
to therapies that target the HER-2 oncoprotein, such as 
Herceptin [2]. Due to the lack of optimal therapeutic 
targets, TNBC represents a specific subtype of breast 
cancer with worst prognosis [1, 2]. Therefore, there 
remains an urgent question to be addressed: Can we 
identity important biological features that serve as high 
value targets for the development of novel treatment 
modalities for TNBC? This line of research carries 
significant social and economic importance.
Hypoxia is one of the major characteristics of solid 
tumors [3]. Upon sensing the oxygen tension, cancer 
cells adapt to the stressful environment and proliferate 
uncontrollably. The key oxygen sensors include three 
EglN family members in humans (termed as EglN1, 
EglN2, and EglN3), which are members of iron and 
2-oxoglutarate-dependent dioxygenases that catalyze 
substrate hydroxylation and mediate their stability 
[4, 5]. For example, hydroxylation of the HIFα (hypoxia-
inducible factor α) by EglN1 generates a binding site 
for a ubiquitin ligase containing the von Hippel Lindau 
(VHL) protein [4]. Previous research show that EglN2 is 
an ER-inducible gene [6, 7]. Moreover, our own research 
demonstrate that EglN2 contributes to ER positive breast 
tumorigenesis by inducing cyclin D1 transcription [8, 9]. 
However, the potential post-transcriptional regulation 
www.impactjournals.com/oncotarget/                      Oncotarget, 2017, Vol. 8, (No. 4), pp: 6787-6795
      Research Paper
Oncotarget6788www.impactjournals.com/oncotarget
of EglN2 and its physiological role in other subtypes of 
breast cancer remain largely unknown.
F-box and WD repeat domain-containing 7 (FBW7) 
is a well-established tumor suppressor in diverse mouse 
and human cancers [10-15]. There are some cancer 
types that harbor high rate of FBW7 mutations/deletions, 
including T-cell acute lymphoblastic leukemia (T-ALL), 
colon cancer, endometrial cancer and cholangiocarcinomas 
[10, 11, 16]. Mechanistically, FBW7 belongs to one of 
F-box proteins that is an essential component of SCF 
(SKP1-CUL1-F-box) E3 ligase complex, which target 
proteins for ubiquitination and degradation [17]. In 
recent years, there are some FBW7 E3 ligase substrates 
identified, including Cyclin E1, c-Jun, c-Myc, Notch1 
and Mcl-1 [18]. Loss of FBW7 in cancer leads to aberrant 
accumulation of these substrates, accounting for the 
tumor phenotypes observed in xenograft or genetic mouse 
models [18]. In breast cancer specifically, FBW7 was 
reported to target mTOR for proteasomal degradation 
[19]. Interestingly, in human breast cancer cell lines and 
primary breast tumors, there exists a reciprocal correlation 
between FBW7 loss and PTEN loss, which also activates 
mTOR [19]. In addition, the FBW7 genetic locus is in 
a region that is frequently deleted in TNBC [20]. This 
suggests an important role of FBW7 in breast cancer.
In this paper, by using both xenograft and mouse 
models, we showed that EglN2 contributes to TNBC 
breast cancer progression. Mechanistically, FBW7 loss in 
TNBC cell lines leads to increased EglN2 protein levels.
RESULTS
EglN2 contributes to TNBC tumor growth
To examine whether EglN2 could play a 
functional role in TNBC, we isolated C3 Tag cell lines 
from mammary tumors of a transgenic line that mimics 
human TNBC development as described previously [21]. 
EglN2 depletion by two independent hairpins (sh744 and 
sh746) in this cell line significantly decreased anchorage 
independent growth (Figure 1A-1C). Next, allograft 
experiments by using EglN2-depleted cell line displayed 
decreased tumor growth and tumor weight compared to 
the control cell line (Figure 1D-1E). These results support 
the important role of EglN2 in TNBC tumor progression, 
which motivated us to cross C3 Tag mice with EglN2 
WT or EglN2 knockout mice. To this end, we generated 
a cohort of C3Tag: EglN2+/+ and C3Tag: EglN2-/- mice. 
While C3Tag: EglN2+/+ mice displayed the median 
survival of 136 days, C3Tag: EglN2-/- mice showed much 
longer survival rate with the median survival of 169 days 
(p=0.0027, Log-rank Mantel-Cox test) (Figure 1F). It is 
worth noting that there appears to be a biphasic tumor 
development for C3Tag: EglN2-/- mice. For the short-term 
survival, there is no distinctive difference between C3Tag: 
EglN2-/- with C3Tag: EglN2+/+ mice but overtime, there 
appears to be a group of mice with prolonged long-term 
survival with C3Tag: EglN2-/- mice. One possibility is 
that EglN2 knockout may not benefit those fast-growing 
tumors but may offer long-term benefits for other slower-
growing tumors. These results suggest the important role 
of EglN2 regulating TNBC tumor growth.
EglN2 protein stability is negatively regulated by 
FBW7
Previous research showed that EglN2 is an ER target 
gene that plays an important role in ER+ breast cancer 
[6, 7]. It remains unclear how EglN2 protein levels may be 
regulated in ER-, especially in TNBC. To further examine 
this, we examined EglN2 protein levels across a panel of 
established breast cancer cell lines. We divided these cell 
lines according to ER expression status (ER+ or ER-). 
Interestingly, a subset of ER- breast cancer cell lines (MCF-
12A, MDA-MB-468, BT-549, Hs-578T, HCC1143 and 
MDA-MB-231) expressed substantial amount of EglN2, 
albeit slightly lower level than ER+ breast cancer cell 
lines including T47D, BT474 and ZR-75-1 (Figure 2A). 
Previous research showed that this subset of ER- breast 
cancer cell lines displayed FBW7 loss [19]. Since FBW7 
is an F-box protein that promotes substrate recognition 
by E3 ligase complex followed by the ubiquitination and 
degradation [22], it is reasonable to postulate that EglN2 
may act as a potential substrate of the FBW7 E3 ligase 
complex in breast cancer. To test this hypothesis, we 
transfected EglN2 in the absence or presence of FBW7 
and found that FBW7 expression decreased EglN2 
protein levels in the cells, a process that can be rescued 
by concurrent treatment with the proteasomal inhibitor 
MG132 (Figure 2B). Consistently, the other two previously 
reported FBW7 substrates c-Myc and c-Jun [23] was 
downregulated by FBW7 expression, the effect rescued 
by MG132 treatment (Figure 2B). In contrast, the protein 
abundance of another EglN family member, EglN1, was 
minimally affected by FBW7 expression, suggesting the 
specific regulation of EglN2 by FBW7.
Since FBW7 is a Cullin1 (Cul1) based E3 ligase 
complex component, we hypothesize that inhibition of 
Cullin-based E3 ligases may also lead to EglN2 protein 
stability. To test that, we transfected cells with EglN2 in 
the presence of dominant negative Cul1, 2, 3, 4a, 4b and 
5 mutants respectively as described previously [24]. These 
dominant negative mutants inhibited their respective E3 
ligase complex activity. Consistently, dominant negative 
Cul1 led to an accumulation of EglN2 protein in cells, 
the effect recapitulated by MG132 treatment (Figure 2C). 
Notably, other known FBW7 substrates Cyclin E1, cMyc 
and cJun were similarly regulated by dominant negative 
Cul1 (Figure 2C). Interestingly, dominant Cul4b also led 
to EglN2 protein upregulation (Figure 2C). However, 
the nature of this finding remains to be determined with 
additional in-depth studies. To show that the proteasomal 
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degradation dependent regulation of EglN2 by FBW7 
may apply for other physiologically relevant system, as 
a complementary approach, we obtained HCT116 colon 
cancer cell lines with or without somatic FBW7 knockout 
and found that EglN2 protein levels was upregulated by 
MG132 treatment in the cell line contain wild type FBW7, 
the effect mimicked by FBW7 loss, suggesting that potential 
EglN2 regulation by FBW7 is mediated by proteasomal 
degradation pathway (Figure 2D). Since the FBW7 genetic 
locus is in a region that is frequently deleted in TNBC [20] 
and the previous research showed that a significant portion 
of ER- breast cancer cell lines displayed FBW7 loss [19], 
hereafter we particularly focus on the effect of FBW7 on 
EglN2 protein levels in breast cancer cell lines.
Depletion of FBW7 leads to increased EglN2 
protein levels in breast cancer
In order to examine the effect of FBW7 on EglN2 
protein levels in breast cancer cell lines, we downregulated 
FBW7 expression levels by two independent hairpins 
in breast cell line MDA-MB-453 with wild type FBW7 
expression and found FBW7 depletion led to increased 
EglN2 and Cyclin E1 levels (Figure 3A). Similarly, 
we depleted FBW7 expression by several independent 
hairpins in two other breast cell lines with functionally 
intact FBW7 (MCF-7 and MCF-10A). Real-time PCR 
confirmed the efficient downregulation of FBW7 in 
these cell lines (Figure 3B and 3D). In addition, we 
also examined protein levels of other FBW7 substrates 
(Cyclin E1, c-Jun or c-Myc) in these cell lines to 
make sure of functional FBW7 downregulation. In 
most cases, we observed an increase in EglN2 protein 
abundance in FBW7 depleted cell lines (Figure 3C and 
3E), suggesting that FBW7 negatively regulated EglN2 
protein levels in breast cancer cells. It is important to 
note that although qRT-PCR analyses showed similar 
FBW7 knockdown efficiency with different hairpins, the 
effects of these hairpins on protein levels of EglN2 or 
canonical FBW7 substrates (Cyclin E1, c-Jun or c-Myc) 
varied to some extent. This could reflect the possibility 
of some uncharacterized off-target effects for a particular 
FBW7 hairpin in a specific cell line. Notwithstanding 
this potential caveat, EglN2 protein upregulation by 
independent FBW7 hairpins in several different breast 
cancer cell lines (Figure 3) or somatic FBW7 knockout in 
Figure 1: EglN2 contributes to TNBC tumor growth. A, B, C. qRT-PCR (A), representative images (B) and quantification (C) of 
soft agar assays from C3Tag cells infected with the lentivirus encoding EglN2 shRNAs (744, 746) or Control (Ctrl) shRNA. The statistical 
significance was calculated using student’s t test. *** denotes p value of < 0.005. Error bars represent one SEM. D, E. Representative 
tumor gross appearance and tumor weight plots for C3Tag cells infected with the lentivirus encoding EglN2 shRNA (744) or Control (Ctrl) 
shRNA implanted into the mammary fat pads in FVB/NJ mice. * denotes p value of <0.05 for comparison between two groups by using 
unpaired two sample t-test. Error bars represent one SEM. F. Kaplan-Meier survival curves for C3Tag: EglN2+/+ and C3Tag: EglN2-/- mice. 
The p value was determined by the Log-rank (Mantel-Cox) test.
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HCT116 cells (Figure 2D) validates its negative regulation 
by FBW7. EglN2 mRNA levels were not robustly affected 
by any of FBW7 shRNAs, suggesting a potential post-
transcriptional regulation of EglN2 by FBW7 (Figure 3B 
and 3D). To examine whether FBW7 depletion increased 
EglN2 protein stability in these cells, we treated MCF-
10A cells with cycloheximide (CHX), an inhibitor for 
protein synthesis, followed by pulse chase with various 
time points. Depletion of FBW7 increased EglN2 
protein stability in these cells (Figure 3F). Consistently, 
for HCT116 cells, somatic FBW7 knockout increased 
exogenous EglN2 protein stability compared to wild type 
controls (Figure 3G). In summary, our data suggests that 
FBW7 depletion increases EglN2 protein stability.
EglN2 C-terminal residues might mediate its 
negative regulation by FBW7
The canonical FBW7 substrate such as Cyclin 
E1 or c-Jun is phosphorylated on threonine residues 
by GSK-3β followed by FBW7 E3 ligase complex 
recognition, ubiquitination and degradation [23]. 
We hypothesize that EglN2 may undergo GSK-
3β dependent phosphorylation followed by FBW7 
recognition and subsequent degradation. To test this 
hypothesis, we used two independent breast cancer 
cell lines that carry FBW7 loss (Hs-578T and MDA-
MB-231) and restored FBW7 protein function by 
using exogenous tagged FBW7. In the presence of 
exogenously tagged GSK-3β, there was a robust 
downregulation of EglN2 protein levels by FBW7 
(Figure 4A-4B), indicating that GSK-3β-dependent 
phosphorylation may mediate EglN2 degradation by 
FBW7 recognition. To test this potential regulation of 
EglN2 by GSK-3β further, we searched the potential 
kinase site for human EglN2 sequence by using the 
previously established method (scansite.mit.edu) and 
found that EglN2 Thr405 is a potential GSK-3β site, 
which is conserved across different mammalian species 
(data not shown).
Figure 2: EglN2 Protein Stability is Negatively Regulated by FBW7. A. Immunoblots from a panel of indicated breast cancer 
cell lines. B. Immunoblots of cell lysates from 293T cells transfected with FLAG tagged EglN2, HA tagged FBW7 or both followed 
by either DMSO (-) or MG132 (10 μM) treatment for overnight. GFP plasmids were transfected as the normalization control for equal 
transfection efficiency. C. 293T cells were transfected with HA-tagged EglN2 in the presence of dominant negative FLAG tagged Cul1, 2, 
3, 4a, 4b, 5 or control (-). Cell lysates were harvested followed by immunoblots as indicated. D. HCT-116 WT or FBW7-/- cells were treated 
with either control (-) or MG132 (10 μM) followed by immunoblots as indicated. Dotted vertical lane for EglN2 indicates that there is a 
non-essential lane that have been removed from a single original gel.
Oncotarget6791www.impactjournals.com/oncotarget
Next, we purified HA tagged EglN2 in cells 
followed by examining its potential phosphorylate sites 
by mass spectrometry. Consistently, we observed that 
Thr405 and adjacent Ser401 sites were phosphorylated 
(Figure 4C), which are towards the very c-terminal of 
EglN2 coding sequence and the stop codon. In order to 
examine the potential role of these sites on regulating 
EglN2 protein levels in the cells, we generated a series 
of EglN2 mutants that contain the single or double 
mutations on these serines or threonines (S401A, T405A, 
ST-AA). Additionally, we also made the EglN2 deletion 
mutants that contain these serines or threonines (∧TPT 
or ∧SQPPTPT). Since these are very small truncation 
mutants that are next to the stop codon, we postulate that 
they may not affect the structural conformation of EglN2. 
Next, we co-transfected EglN2 WT or mutants with 
tagged GSK-3β and FBW7. It is important to note that 
the basal levels of WT or EglN2 mutants in the absence 
of GSK-3β displayed some variance, which awaits further 
investigation. Whereas wild type EglN2 was degraded in 
the presence of GSK-3β and FBW7, all of mutants escaped 
the GSK-3β and FBW7 mediated degradation (Figure 4D), 
strengthening the notion that EglN2 C-terminal Threonine 
or Serine residue may mediate its regulation by FBW7, 
potentially through GSK-3β mediated phosphorylation. 
Consistently, we observed the interaction between FBW7 
and EglN2 in cells, whereas the binding diminished for 
EglN2 C-terminal mutants (Figure 4E), suggesting that 
EglN2 C-terminal may be important for its interaction 
with FBW7 therefore affecting its protein stability. Lastly, 
we examined the ubiquitination of EglN2 by FBW7 and 
found that FBW7 robustly promoted wild type EglN2 
ubiquitination, the effect totally abrogated in EglN2 
mutants that contain S401A, T405A or ST-AA mutations 
(Figure 4F) Accumulatively, our data suggests that 
EglN2 C-terminal sequence may mediate EglN2 binding 
with FBW7 followed by its ubiquitination, therefore 
contributing to its protein stability regulation.
DISCUSSION
In this study, we showed for the first time that EglN2 
plays an important role contributing to TNBC tumor 
growth. Mechanistically, FBW7 loss in TNBC cells leads 
to upregulation of EglN2 protein levels. Hence, EglN2 
protein stability is negatively regulated by the FBW7 
E3 ligase complex. Depletion of FBW7 in breast cancer 
cells results in EglN2 protein upregulation. In addition, 
we also identified several EglN2 phosphorylation sites on 
its C-terminal that may mediate its binding, ubiquitination 
and protein stability regulation by FBW7. Our findings 
suggest that EglN2 may contribute to TNBC tumor growth 
as a downstream target of FBW7.
There are multiple layers of protein regulation 
in the cells, including both transcriptional and post-
transcriptional regulations. For example, in ER+ breast 
cancer, EglN2 is mainly regulated by estrogen and acts as 
a canonical estrogen inducible gene [6, 7]. In this setting, 
EglN2 contributes to Cyclin D1 regulation in an enzymatic 
dependent manner and regulates mitochondrial function 
Figure 3: Depletion of FBW7 Leads to Increased EglN2 Protein Levels in Breast Cancer. A. Immunoblot analysis of MDA-
MB-453 cells infected with the lentivirus encoding FBW7 shRNA (#1, #6) or control (Ctrl) shRNA. B-C. qRT-PCR (B) or immunoblot (C) 
or analysis of MCF-7 cells infected with the lentivirus encoding either FBW7 shRNA (#1, #4, #5) or control (Ctrl) shRNA. D-E. qRT-PCR 
(D) or immunoblot (E) analysis of MCF-10A cells infected with the lentivirus encoding FBW7 shRNA (#1, #4, #6) or control (Ctrl) shRNA. 
F-G. Immunoblot analysis from cycloheximide (CHX) pulse chase of MCF-10A cells infected with the lentivirus encoding FBW7 shRNA 
(#1) or control (Ctrl) shRNA (F) or HCT-116 WT or FBW7-/- cells expressing exogenous Flag tagged EglN2 (G).
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in an enzymatic independent manner [8, 25]. From this 
perspective, it may be necessary to deplete EglN2 protein 
level completely in order to have the durable anti-tumor 
efficacy in vivo. In ER- breast cancer, we report here that 
EglN2 protein stability is potentially regulated by SCFFBW7 
E3 ligase complex. Interestingly, FBW7 locates in a 
region that harbors the genomic loss frequently observed 
in TNBC [20]. TNBC patients display significant lower 
FBW7 expression compared to normal breast controls 
and FBW7 copy number loss predicts a worse prognosis 
(Zhang Q, unpublished data), indicating the important role 
of FBW7 in TNBC. Therefore, frequent loss of FBW7 in 
TNBC may contribute to higher EglN2 protein levels and 
promote breast tumorigenesis. It remains to be determined 
whether the phenotype induced by FBW7 loss in TNBC 
is mediated through EglN2 or potentially other substrates. 
It will be also interesting to see how EglN2 contributes 
to TNBC and whether its enzymatic activity may be 
important for its effect on TNBC tumor progression.
Our findings further show that C-terminal of EglN2 
may be important for its binding with FBW7, therefore 
contributing to its protein stability regulation by this E3 
ligase complex. Consistently, we show that various EglN2 
C-terminal mutants escape the degradation by FBW7. By 
mass spectrometry, we also identify two phosphorylation 
sites on EglN2 C-terminal Threonine (aa 405) and 
Serine (aa 401) residues. Interestingly, the Thr405 site 
is predicted to be a canonical GSK3β kinase site. Since 
GSK3β is reported to be the main kinase that promotes 
FBW7 substrate phosphorylation followed by the E3 ligase 
complex recognition [23], it is reasonable to hypothesize 
that Thr405 site may be a GSK3β kinase site that mediate 
EglN2 protein stability regulation by FBW7. Although 
our data show that FBW7 promotes EglN2 degradation 
in a GSK3β kinase dependent manner, we have not 
observed the GSK3β kinase induced EglN2 Thr405 site 
phosphorylation when performing the in vitro kinase assay 
with GST-tagged EglN2. There are several possibilities: 
Figure 4: EglN2 C-terminal Residues Might Mediate Its Negative Regulation by FBW7. A-B. Immunoblot analysis of 
Hs-578T (A) and MDA-MB-231 (B) cells co-transfected with HA tagged FBW7 or GFP with either HA-tagged GSK3β or Control. Cell 
lysates were harvested 48 hours post-transfection. C. 293T cells were transfected with either HA tagged EglN2 or control followed by 
immunoprecipitation with HA agarose beads (3F10, Roche). Coomassie staining was performed to visualize the purified HA EglN2, 
which was cut followed by mass spectrometry analysis as described previously. EglN2 Ser401 and Thr405 sites were shown to be 
phosphorylated. D. Immunoblots for 293T cells co-transfected with various FLAG tagged EglN2 constructs (WT, S401A, T405A, ST-
AA, ∧TPT or ∧SQPPTPT) and HA tagged GSK3β or Control (-). Equal amount of GFP was transfected to make sure of comparable 
transfection efficiency. Cell lysates were harvested 48 hours post-transfection. E. Immunoblot (IB) assays of whole cell extract (WCE) and 
immunoprecipitation (IP) of 293T cells (expressing Ctrl or HA-FBW7) co-transfected with Flag-EglN2 (F-EglN2), Flag-EglN2 ST-AA, 
Flag-EglN2 ∧SQPPTPT, Flag c-Jun or Flag c-Jun FS-AF mutants. Cells were treated with MG132 (10 μM) for overnight before harvesting 
at 48 hours post-transfection. F. In vivo ubiquitination assays of immunoprecipitation (IP with Ni-NTA) of 293T cells (expressing Ctrl or 
HA-FBW7) co-transfected with Flag-EglN2 (WT), Flag-EglN2 S401A, T405A or ST-AA. Cells were treated with MG132 (10 μM) for 
overnight before harvesting at 48 hours post-transfection.
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First, it may be possible that EglN2 needs to be modified 
or primed in nearby residues in order for the Thr405 site to 
be efficiently phosphorylated by the GSK3β kinase. This 
is highly likely since we also observed that Ser401 site is 
phosphorylated in vivo by mass spectrometry. Second, it 
is also possible that there may be other unknown or non-
canonical GSK3β kinase site in EglN2 sequences that need 
to be further characterized. Third, it is also likely that there 
may exist other kinases that may regulate EglN2 protein 
stability. In fact, by treating cells expressing exogenous 
EglN2 with different kinase inhibitors, we found that in 
addition to the GSK3β kinase inhibitor, the pan CDK 
inhibitor can also increase exogenous tagged EglN2 
expression (Zhang Q, unpublished data).
Taken together, our results identify EglN2 as a 
potential therapeutic target in TNBC, and show that FBW7 
may regulate EglN2 protein stability in breast cancer. 
FBW7 loss induced EglN2 protein stabilization contributes 
to TNBC tumor progression, which offers a potential 
novel therapeutic avenue in treating this lethal disease.
MATERIALS AND METHODS
Cell cultures
293T, MDA-MB-157, MDA-MB-468, MDA-
MB-453, HS-578T, MDA-MB-231, HCT116 cells were 
cultured in DMEM containing 10% fetal bovine serum 
(FBS) supplemented with 1% Pen/Strep. T47D, BT-474, 
ZR-75-1, HCC70, HCC1937, BT-549 and HCC1143 were 
cultured in RPMI medium containing 10% FBS and 1% 
Pen/Strep. MCF-10A and MCF-12A cells were cultured in 
DMEM/F12 media with 5% Horse serum, 20 ng/ml EGF, 
100 ng/ml cholera toxin, 0.01 mg/ml insulin and 500 ng/
ml hydrocortisone as described previously [26]. SKBR3 
cells were maintained in McCoy5A media supplemented 
with 10% FBS +1% Pen/Strep. HCT116 WT and FBW7-
/- cells were kindly provided by Dr. Bert Vogelstein 
(Johns Hopkins University) [27] and were cultured in 
DMEM with 10% FBS +1% Pen/Strep as described 
previously [28]. Following lentivirus infections, cells were 
maintained in the presence of puromycin (2 μg/ml). All 
cells above were maintained at 37°C in 5% CO2 incubator.
Western blot analysis and antibodies
Whole cell lysates were harvested by using EBC 
buffer (50 mM Tris pH8.0, 120 mM NaCl, 0.5% NP40, 
0.1 mM EDTA and 10% Glycerol) supplemented with 
complete protease and phosphatase inhibitors (Roche 
Applied Biosciences). Cell lysate concentrations were 
measured by Bradford assay (Biorad) followed by SDS-
PAGE analysis with equal amount of lysates supplemented 
with 3xSDS loading dye. Rabbit EglN2 antibody (NB100-
310) was from Novus Biological. Rabbit anti Cyclin D1 
(RB-010-P1) was from Neomarker. Antibodies against 
Vinculin (V9131), Tubulin (T9026) and FLAG (A8592) 
were from Sigma. Cyclin E1 (SC-247), c-Myc (SC-40), 
GFP (SC-9996) antibodies were from Santa Cruz. c-Jun 
(9165), p27 (3688) and EglN1 (3293S) antibodies were 
from Cell Signaling. HIF1α antibody (610959) was 
obtained from BD Bioscience. Mouse antibody against 
hemagglutinin (HA, MMS-101P) was obtained from 
Covance. Mouse Peroxidase conjugated goat anti-mouse 
secondary antibody (31430) and peroxidase conjugated 
goat anti-rabbit secondary antibody (31460) were 
purchased from Thermo Scientific.
Immunoprecipitation
Cells were lysed in EBC lysis buffer supplemented 
with complete protease and phosphatase inhibitors 
(Roche Applied Bioscience). The lysates were cleared by 
centrifugation and then mixed with 3F10 HA conjugated 
beads (Roche Applied Bioscience) or FLAG M2 beads 
(Sigma) overnight. The bound complexes were washed 
with NETN buffer (120 mM NaCl, 20 mM Tris-HCl (pH 
8.0), 0.5 mM EDTA, 0.5 % (v/v) Nonidet P-40 (NP-40) for 
8 times and were eluted by boiling in SDS loading buffer. 
Bound proteins were resolved in SDS-PAGE followed by 
western blot analysis.
Virus production and infection
293FT packaging cell lines was used for lentiviral 
amplification for EglN2 shRNAs or FBW7 shRNAs. 
Lentiviral infection was carried out similarly as previously 
described [8]. Briefly viruses were collected twice at 48 
and 72 hours post-transfection with lipofectamine 2000 
and helper plasmid pSPAX2 and pMD2G. After getting 
rid of the cell debris by passing through 0.45 μM filters, 
viruses were used to infect target cells in the presence of 8 
μg/ml polybrene. Subsequently, target cell lines underwent 
puromycin (2 μg/ml) selection. Lentiviral shRNAs were 
obtained from Broad Institute TRC shRNA library. Target 
sequences are listed as follows:
Ctrl shRNA: AACAGTCGCGTTTGCGACTGG
EglN2 sh744: CGTTGAGTGTAGAGCTGAGAA
EglN2 sh746: GAATCAGAACTGGGATGTTAA
 FBW7 shRNA #1: AACCTTCTCTGGAGAGA 
GAAA
FBW7 shRNA #4: CCAGAGAAATTGCTTGCTTTA
FBW7 shRNA #5: CCAGTCGTTAACAAGTGGAAT
FBW7 shRNA #6: CCAGAGACTGAAACCTGTCTA
Plasmids
Dominant negative FLAG Cul1, 2, 3, 4a, 4b and 
5 plasmids were obtained from Addgene. Flag-EglN2 
was described in the previous publication [25]. HA 
tagged EglN2 was amplified by PCR with a 5’ primer 
that introduced a HA tag with a HINDIII site and a 3’ 
primer that introduced an EcoRI site. The PCR product 
was digested with HINDIII and EcoRI and cloned into 
Oncotarget6794www.impactjournals.com/oncotarget
the pcDNA3.1 vector cut with these two enzymes. HA 
tagged FBW7, HA-GSK3β, FLAG c-Jun and FLAG c-Jun 
FS-AF plasmids were described previously [29]. FLAG-
EglN2 S401A, T405A, ST-AA, ∧TPT and ∧SQPPTPT 
were created by using site-directed mutagenesis (Agilent 
Technology). All plasmids were sequenced to make sure 
of correct sequence.
Real-time RT-PCR
Total RNA was isolated with RNeasy mini 
kit (Qiagen). First strand cDNA was generated 
with the iScript cDNA synthesis kit (Biorad). Real 
time PCR was performed in triplicate as described 
before [8]. Real-Time RT-PCR primers used in this 
study are listed as below: β-actin (human) (Forward: 
AGAAAATCTGGCACCACACC; Reverse: GGGGT 
GTTGAAGGTCTCAAA) ; FBW7 (human) (Forward: 
TGGACCATGGTTCTGAGGTCCGC; Reverse: TTCGG 
CGTCGTTGTTGCCCT); EglN2 (human) (Forward: 
AACATCGAGCCACTCTTTGAC; Reverse: TCCTTG 
GCATCAAAATACCAG); Actin (mouse) (Forward: 
ACCAACTGGGACGACATGGA; Reverse: GGTCTCAA 
ACATGATCTGGGTCAT); EglN2 (mouse) (Forward: 
CTGGGCAACTACGTCATCAAT; Reverse: TGCACC 
TTAACATCCCAGTTC).
Orthotopic tumor growth and animal 
experiments
Ten to eleven week old female FVB/NJ mice were 
used for xenograft studies. Approximately 4 x106 viable 
C3Tag cells with either Ctrl shRNA or EglN2 shRNA 
(sh744) were resuspended in 100 μl growth factor reduced 
matrigel (BD biosciences) and injected orthotopically into 
the mammary gland as described previously [8]. Mice 
were sacrificed ten weeks after tumor implantation. The 
total mass of tumors was presented as mean ± SEM and 
evaluated statistically using a t test. EglN2-/- mice were 
obtained from Regeneron Pharmaceuticals and were 
backcrossed to pure FVB/NJ background. C3Tag mice 
were obtained from Jackson Lab. For mice crossing 
between C3Tag and EglN2-/-, they were regularly 
monitored and euthanized when their tumor size reaches 
20 mm (2.0 cm) in diameter. The survival time was 
calculated from the birth of mice to the day of sacrifice. 
All animal experiments complied with National Institutes 
of Health guidelines and were approved by the University 
of North Carolina at Chapel Hill Animal Care and Use 
Committee.
Soft agar assay
First, 3% agarose (Sigma, A-4018) is prepared in 
water followed by the autoclave. Then, the agarose will 
be diluted with complete growth media to make 1% of 
agarose/media stock for the bottom layer. Then, 0.8% 
agarose will be made in order to mix with cells to make 
0.4% agarose for the top layer. Cells were grown at 
37°C in 5% CO2 incubator for three weeks followed by 
the staining with iodonitrotetrazolium chloride (Sigma) 
solution for staining and foci counting.
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